Zentek Ltd Stock Price, News & Analysis

Zentek (NASDAQ:ZTEK)(TSXV:ZEN) has provided an update on the commercialization of its ZenGUARD™ Antimicrobial Surgical Masks. Following a Canada-wide sampling program for dental professionals through Henry Schein Inc., the company is experiencing increased demand for its product. Zentek is exploring opportunities in the beauty space and international healthcare markets. The company has applied to the FDA for authorization to sell ZenGUARD™ Surgical Masks in the United States and is currently evaluating additional information requests from the FDA.

CEO Greg Fenton highlighted that ZenGUARD™ masks not only provide better protection against infectious agents but also eliminate 99.9% of bacteria that can cause acne when wearing masks for extended periods. This unique value proposition is expected to drive demand in the dental market and potentially in the beauty industry.

Zentek (NASDAQ: ZTEK) (TSXV: ZEN) held its annual and special meeting of shareholders on September 26, 2024. Shareholders voted in favor of all resolutions presented. The meeting included the election of directors, with all nominees listed in the Management Information Circular being elected. Voting results for directors ranged from 81.258% to 98.899% in favor.

Shareholders also approved the appointment of BDO Canada LLP as the Company's auditors with 99.275% of votes in favor. Additionally, the Company's omnibus long-term incentive plan was approved and confirmed with 82.077% of votes in favor and 17.923% against.

The Management Information Circular, dated August 19, 2024, containing details of all resolutions, is available on the Company's SEDAR+ profile.

Zentek (NASDAQ: ZTEK) (TSXV: ZEN) has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement. The company's shares have traded below $1.00 for 31 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Zentek has until March 10, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. If unsuccessful, the company may be eligible for an additional 180-day grace period. Failure to meet requirements could result in delisting, though Zentek can appeal such a decision. The company's management is actively monitoring the situation and considering options to address the deficiency.

Zentek (Nasdaq:ZTEK, TSXV:ZEN) has announced plans for a normal course issuer bid, subject to regulatory approval. The company aims to repurchase up to 5,084,319 common shares, representing approximately 5% of its outstanding shares, over a one-year period from August 16, 2024, to August 15, 2025. Zentek can purchase up to 2,033,727 shares (2% of outstanding shares) in any 30-day period during the bid.

Management believes this strategy will increase long-term shareholder value, as the current market price may not fully reflect the company's business value and future prospects. Purchases will be made through the TSX Venture Exchange at market prices, with Integral Wealth Securities appointed as the broker for these transactions.

Zentek (Nasdaq:ZTEK)(TSX-V:ZEN) has announced preliminary battery results and a new three-year, $441,000 project in collaboration with the University of Toronto. The project, funded by an NSERC Mission Alliance Grant, aims to optimize graphite for battery anode use. Key highlights include:

1. Preliminary results show a minimum 17% increase in capacity for pouch cell batteries using engineered Albany graphite compared to commercial-grade anode material.

2. This project complements a $1.6M Mitacs research project announced in October 2022, focusing on multifunctional materials for automotive batteries.

3. Zentek is exploring both graphite production from its Albany Deposit and graphite processing for battery-ready anode material.

The company aims to develop premium anode materials that outperform commercial anodes in energy capacity, cycle life, and charging rate.

Zentek (NASDAQ:ZTEK, TSXV:ZEN) has announced a nationwide sampling program for its ZenGUARD™ Antimicrobial Surgical Masks in Canada, facilitated by Henry Schein Inc. The program targets dental professionals, with ZenGUARD™ masks to be included in product shipments to Henry Schein customers.

Key features of ZenGUARD™ masks include:

• Enhanced protection against infectious agents
• 99.9% elimination of bacteria
• Reduction of mask-related acne
• Superior filtration compared to standard ASTM Level 3 surgical masks

Zentek CEO Greg Fenton emphasized the importance of safety in dental practices and positioned ZenGUARD™ technology as the new standard for protection in this market segment.

Zentek (NASDAQ:ZTEK)(TSXV:ZEN) announced that its subsidiary, Albany Graphite (AGC), has achieved 99.99915% purity for a graphite sample from the Albany deposit. This ultra-high purity was attained using a two-step process without hydrofluoric acid. The material will be tested for lithium-ion battery anodes and evaluated for the nuclear market.

The company is exploring both graphite production and processing to create battery-ready anode material. An updated mineral resource estimate shows Indicated Mineral Resources of 22.9 million tonnes at 4.1% graphitic carbon and Inferred Mineral Resources of 13.1 million tonnes at 2.9% graphitic carbon. The Albany Graphite Project is located near infrastructure in Ontario, Canada, and has shown potential to compete with synthetic graphite in various applications.

Zentek (NASDAQ: ZTEK) has announced the grant of stock options to directors, officers, and employees. The grant includes a total of 1,935,000 common shares, priced at $1.52 per share, exercisable over the next five years.

For directors and officers, the options will vest in three installments: one third on the date of the grant, one third on the first anniversary, and one third on the second anniversary. Employees will see their options vest in four installments: one quarter on the date of the grant and one quarter annually thereafter.

Zentek has been granted a second patent by the Canadian Intellectual Property Office for its Graphene Oxide-Cationic Silver (GO-Ag+) Nanocomposites, recognized as a broad-spectrum antimicrobial agent.

The patent includes 64 successful claims and covers the compound's use against bacteria, fungi, and viruses in various forms such as liquid, powder, and ointments. Zentek has also applied for this patent with the U.S. Patent and Trademark Office.

GO-Ag+ has shown higher cytotoxicity against bacteria than human cells and is being studied for its effectiveness in preventing and eliminating biofilms, a significant challenge in wound care and medical devices. The patent supports further development of GO-Ag+-based products for medical and veterinary markets.

CEO Greg Fenton emphasized that this milestone is important for Zentek's intellectual property commercialization strategy and aims to maximize shareholder value.